Objective: To estimate the cost-effectiveness of alternative interventions to reduce the risk of mother-to-child transmission of HIV. Design: A model capturing the sequential nature of mother-to-child transmission in utero, at delivery and postnatally was used to determine how the effects of bottlefeeding, elective Cesarean section (CS) and zidovudine (ZDV) would combine to prevent mother-to-child HIV transmission. Parameter estimates were derived from the literature, UK health service costs applied, and incremental cost effectiveness ratios (ICER) estimated for alternative risk reduction strategies. Results can be transposed to other cost assumptions or currencies.
Introduction
The risk of HIV transmission from an infected mother to her child ranges from 15% to 40%, the lowest rates being reported in Europe, and the highest in African countries where most women breast-feed [1] . However, if women know their HIV status during pregnancy, avoidance of breast-feeding [2] administration of zidovudine (ZDV) antiretroviral therapy in pregnancy, at delivery and to the newborn [3] and the avoidance of invasive procedures shown to increase transmission during pregnancy and intrapartum [4, 5] can result in a reduction in transmission to 5-8%. This has already been achieved in parts of Europe and the USA [6, 7] . This paper reports on a model of alternative intervention strategies to reduce the risk of mother-to-child transmission of HIV infection and estimates the health service costs and incremental cost-effectiveness ratios (ICER) -additional cost per extra vertical HIV transmission avoided -of these strategies. Use and costs of interventions in current practice in the UK [encouragement of bottle feeding, use of ZDV and use of elective Cesarean section (CS)] are applied to the model to assess the relative cost-effectiveness of progressively more expensive risk reduction strategies compared with the baseline risk that would exist had no active strategy been adopted. The ICER of ZDV at different rates of elective CS delivery and the ICER of elective CS at different rates of ZDV use are explored. Extension of the model to other situations and other interventions is discussed.
Methods Transmission risk model and its parameters
A model of vertical transmission was developed with parameters for the probabilities with which different combinations of interventions were used, and for the vertical transmission risk attached to each combination.
The vertical transmission component of the model made explicit the sequential nature of mother-to-child exposure to HIV: during pregnancy in utero and during delivery (vaginal or Cesarean), and via breast-feeding ( Fig. 1 ).
For example, in untreated women delivered by elective CS, a proportion u of all infants have been infected in utero; and the fraction (1-u) who escaped infection in utero are then at risk of infection at (elective) CS delivery. The overall risk in this group is, therefore, C = u + c (1-u) . Similarly, those not infected at or before delivery, are then at risk of transmission by breast-feeding. The risk in breast-fed children delivered by elective CS to untreated mothers is, therefore, C + b (1 -C). In the absence of data to the contrary, it is assumed that the effect of ZDV is to reduce all components of transmission by the same factor, z. In a treated woman the risks of transmission in utero, during elective CS delivery, during vaginal or emergency CS delivery and through breast-feeding, are u/z, c/z, v/z and b/z respectively. It is thereby assumed, and there are no data to support or refute this, that the effect of ZDV in reducing transmission risk is the same at each stage. A treated woman delivering by elective CS has an overall risk of transmission
The literature does not provide direct information on the five parameters v, u, b, c and z, but it does provide estimates of functions of the parameters, from which the parameters themselves can be estimated. Details are given in the Appendix, and estimated parameter values are shown in Fig. 1 . Also given in the Appendix is the method used to estimate 95% confidence intervals (CI) for transmission parameters vertical transmission risks and ICER. The CI throughout the paper simultaneously take account of all the statistical uncertainty in the source literature.
Cost parameters
The cost analysis takes a health service perspective and each intervention has been costed on a per woman basis. The average cost of ZDV therapy is estimated at UK£914, based on published recommended dosages and prices [8, 9] . This cost includes the cost of administering the drug to the woman antenatally for a period of 11 weeks (the average period that women received ZDV antenatally during the AIDS Clinical Trials Group 076 trial) and during labour, and to the child during the first 6 weeks of life [3] . During delivery, the drug is administered intravenously, and costs of equipment and personnel time are included based upon detailed discussions with three London maternity units in 1996.
The cost (sterling) of an elective CS is estimated at £1052, a vaginal delivery at £400 and an emergency CS at £1289 based on a study of 36 000 singleton deliveries in 17 hospitals in south-east England [10] . Assuming, from routine data collected in south-east England, that 92.5% of non-elective CS (vaginal or emergency) [11] deliveries are vaginal and the remaining 7.5% are emergency CS, the average cost of nonelective CS (vaginal or emergency CS) deliveries is £466.70, and the average additional cost of elective CS is £585.30. The quoted cost figures have been up-dated to 1996 prices using the NHS price inflation index [12] .
All pregnant women are routinely counselled about breast-feeding and no additional costs have been assigned to the process of counselling associated with discouraging women with HIV infection from breastfeeding. However, an estimated 40% are prescribed bromocriptine to suppress the production of breast milk. This has been costed using British National Formulary (1996) prices [8] , giving an average cost of £2.11 per woman who bottle-feeds.
Economic analysis
The cost-effectiveness of alternative risk reduction strategies is evaluated in terms of their vertical transmission probabilities and the average costs of each strategy. Each intervention strategy can be characterized in terms of the proportions of women (pathway probabilities in Fig. 1 ) taking up each of the eight treatment combinations (pathways). The total cost is the weighted sum of the individual pathway costs, using the pathway probabilities as weights ( Fig. 1) . Similarly, the overall risk of vertical transmission is the weighted sum of the cumulative probability of transmission associated with each pathway.
Once a woman's HIV status is known, she will be encouraged to bottle-feed, so that all strategies evaluated here have a bottle-feeding component. Four risk reduction strategies are modelled and compared with a baseline of no active intervention: bottle-feeding alone (S1); bottle-feeding plus elective CS (S2); bottle-feeding plus ZDV (S3); and bottle-feeding plus ZDV plus elective CS (S4).
The evaluation of cost-effectiveness consists of three distinct analyses. The first analysis takes a clinical viewpoint where the individual woman will either undergo a particular intervention or she will not. The second analysis takes a public health policy perspective, which introduces uncertainty about the rates of uptake of particular interventions. Rates of uptake of the three risk reduction interventions have been reported recently in Table 1 . Transmission rates, expected costs and cost-effectiveness of alternative strategies from the clinical viewpoint. *ED, Subject to extended dominance; that is, a more effective option (S3) has a lower incremental cost effectiveness ratio [15] . ZDV, Zidovudine; CS, Cesarian section; CI, confidence interval; B, baseline of no active intervention; S1-24, risk reduction strategies (see Methods). the UK [13] . Specifically, these include 96% bottlefeeding, 44% elective CS, and 75% ZDV use among women who are aware of their HIV infection during pregnancy. Among those who are unaware of their infection, it has been estimated that 34% bottle-feed [13] , and it can be assumed that they undergo elective CS at the normal rate of 6% [14] ; none takes ZDV.
Uptake of interventions
The third analysis adopts the public health viewpoint and takes the form of graphically presented sensitivity analyses. The level of bottle-feeding is held at the currently observed rate (96%), and the ICER of ZDV therapy at different levels of uptake of CS and the ICER for CS at different levels of ZDV use are then explored.
In order to make it possible to apply different unit costs or currencies, simple methods for transposing the findings are given for each analysis. Table 1 shows the transmission risk, expected costs and ICER of the four risk reduction strategies compared with the baseline from the clinical viewpoint. The encouragement of bottle-feeding (S1) generates the greatest reduction in transmission risk (31.6-17.7%) at a low incremental cost per transmission avoided of only £15. Adding elective CS to the encouragement of bottle-feeding (S2) generates a transmission risk reduction from 17.7% to 11.3% with an ICER of £9186 and is, therefore, subject to extended dominance [15] ; that is, ZDV with bottle-feeding is more effective and has a lower ICER relative to elective CS with bottle-feeding. Although elective CS with bottle-feeding is subject to extended dominance at baseline values of the transmission parameters, the simulations also show that it would be possible to find parameter values well within the plausible range under which this strategy would not be subject to extended dominance. Strategy S3 (bottle-feeding with ZDV administration) reduces the risk of transmission to 5.8% with an ICER relative to bottlefeeding alone of £7658. Adding elective CS to bottlefeeding and ZDV reduces transmission risk a further 1.9% to 3.7%, with an ICER of £27 836 relative to ZDV and bottle-feeding. Table 2 shows the results of the second analysis based on a public health viewpoint and using rates of uptake of interventions recently reported in the UK [13] . The encouragement of bottle-feeding (S1) generates the greatest reduction in transmission risk (from 26.5% to 17.9%). Adding elective CS to the encouragement of bottle-feeding (S2) only generates a transmission risk reduction from 17.9% to 15.5%, whereas adding the use of ZDV to the encouragement of bottle-feeding (S3) reduces the risk of transmission to 8.8%. Use of all three interventions (S4) reduces transmission risk by a further 1.2% to 7.6%. The ICER remain similar to the clinical viewpoint in Table 1 , but differ because the ICER of CS and ZDV each depend upon the uptake of the other. This is shown in Fig. 2 which plots the ICER of ZDV as a function of the uptake of CS. The points on the curve where the uptake of CS is 6% and 44% are equivalent to the comparison of S3 and S1 in *ED, Subject to extended dominance; that is, a more effective option (S3) has a lower incremental cost effectiveness ratio [15] . ZDV, Zidovudine; CS, Cesarian section; CI, confidence interval; B, baseline of no active intervention; S1-S4, risk reduction strategies (see Methods).
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Fig. 2.
Incremental cost-effectiveness ratio (ICER) of zidovudine at increasing acceptance of elective Cesarian section delivery assuming 96% bottle-feeding. Dashed lines represent the 95% confidence intervals. Similarly, Fig. 3 plots the ICER of CS as a function of the uptake of ZDV. The ICER of CS rises more sharply than that of ZDV, from £9248 to £27 895 with increasing use of ZDV. The upper CI of the ICER at 100% uptake of ZDV is particularly high (£154 462), reflecting uncertainty in the parameters, particularly around the efficacy of CS.
The cost-effectiveness of the strategies is also influenced by the assumptions made about the underlying parameters. Of particular interest is the relationship between the ICER of CS and the assumed odds ratio (OR) of transmission during CS: vaginal delivery which is esti-mated here to be 0.59 (Appendix) with a 95% CI of 0.36-0.98. Figure 4 shows that the ICER of CS rises very steeply: to £50 000 when the OR is 0.77; £100 000 when it is 0.88; and £150 000 when it is 0.92.
Costs of interventions may vary widely from those used in the UK. However, simple transposition of ICER enables the present results to be applied to any set of assumptions. For example, ICER for elective CS are based on an average cost difference of UK£585 between elective CS and non-elective CS delivery. To recalculate ICER in Fig. 2 and Fig. 3 for a cost difference of, for example US$5000, they should be multiplied by 5000/585 and read as US$. ZDV ICER are based on a cost of £914 and this value can be used to transform ICER in a similar way.
Discussion
The costs to the woman associated with bottle-feeding (e.g., purchase of bottles, milk and sterilizing equipment) have not been included, as the focus of this analysis concerns only those costs directly attributable to the health service. The results show that bottle-feeding has a very low incremental cost per transmission avoided and the inclusion of costs to women is unlikely to increase this markedly. As noted earlier, no additional costs have been assigned to the process of counselling associated with discouraging women with HIV infection from breast-feeding. However, even if an additional cost of £50 per woman was included to reflect this, bottle-feeding would still have a very low incremental cost per transmission avoided relative to the other interventions considered.
In London, where the majority (approximately 80%) of women who have acquired HIV in Africa are undiagnosed in pregnancy and breast-feed their infants [13] , the important task is clearly to increase the detection of HIV infection in pregnancy [16] . Recent data have shown that infected women, aware of their HIV status, are about 15 times more likely to bottle-feed than those who remain unaware [13] .
The efficacy of ZDV antiretroviral therapy in addition to bottle-feeding, in reducing mother-to-child HIV transmission, is now well established, both in a trial situation [3] and in clinical practice [6, 7] . This analysis shows that ZDV therapy is likely to have a relatively low ICER under any plausible assumptions.
Conversely, adding elective CS to bottle-feeding is less cost-effective and, at base-case parameter values, is subject to extended dominance by the bottle-feeding plus ZDV option. At the same time, however, it was found that an absence of extended dominance was compatible with plausible transmission parameter values. Although there is a growing literature on mode of delivery and vertical HIV transmission, there is no consensus on the effect of elective as compared with emergency CS. The present evaluation is based on the most recent analysis of the CS [4] , in which elective CS is carried out before labour at 38 weeks gestation, and is clearly beneficial although the 95% CI is very wide. Data from other cohort studies [17, 18] show no benefit but the distinction between emergency and elective CS is less clear. The results obtained here are sensitive to both the cost and the effectiveness assumptions implied. They certainly suggest that it would be worthwhile to obtain a more precise estimate of the effectiveness of elective CS delivery. For example, if the OR of transmission through elective CS:vaginal or emergency CS delivery is above 0.8, the ICER of elective CS rises very steeply. More precise estimates will be obtained from the more comprehensive meta-analysis of data from all observational studies of mother-to-child transmission worldwide which is currently being carried out in the USA, or from the randomized trial of elective CS versus vaginal delivery in Europe [19] .
The extent to which this uncertainty about the efficacy of elective CS influences the cost-effectiveness of the strategies depends on relative variation in the cost of ZDV, vaginal delivery and elective CS. For example, assuming that the baby is bottle-fed, ZDV is more costeffective than elective CS (i.e., CS remains subject to extended dominance) unless either ZDV were to cost more than £1096 (base-case £914), or the difference in cost between vaginal delivery and elective CS was to be less than £488 (base-case £585). More generally, over and above bottle-feeding, ZDV is more costeffective than elective CS so long as the ratio of ZDV costs to the additional costs of elective CS (base-case 1.562) is less than (1 -V z / V) / (1 -C / V), which is 1.873 under base-case assumptions.
Assuming current rates of uptake observed in the UK [13] , combining all three interventions (bottle-feeding 96%, ZDV 75% and elective CS delivery 44%) is the most effective strategy and yields an incremental cost per transmission avoided of £18 546 over bottlefeeding and ZDV alone. Although this is relatively expensive, the life-time costs of care for an HIVinfected child have been reported to be as much as $420 000 in the USA [20] . Mandalia et al. calculated the cost of care for a child with AIDS to be £36 990 per child-year from data at a London hospital for the period 1986-1994 [21] . Costs are likely to be even higher with increased use of expensive antiretroviral therapies which require more outpatient monitoring and result in children living longer. This would argue for use of all of the interventions. However, from a public health perspective, it might be better to attempt to increase the uptake of ZDV to 100%, rather than to spend money on elective CS, at least until better data on its efficacy are available.
The model presented in this paper captures the separate risks of transmission in utero, at delivery and postpartum and is explicit in showing how the different interventions combine. This contrasts somewhat with the use of logistic regression in prospective studies [4] which assumes that the transmission risks of breastfeeding, vaginal delivery and elective CS are additive on a log-odds scale. Models of the type presented here may be of value not only in economic analyses, but in research into the mechanisms and timing of motherto-child transmission and in comparing the relative efficacy of different interventions. The model could also be extended to permit analyses of other interventions such as immunotherapy, policies of offering elective CS only to women with prolonged rupture of membranes [5] and vaginal lavage. Although the results of the Malawi trial of vaginal lavage with chlorhexidine showed no benefit [22] , if this approach was shown to be efficacious using other virucidal agents it could have important advantages in the developing country setting. It has the potential for a low cost, safe intervention which could be applied to all women, obviating the need for and costs of HIV testing in pregnancy.
A further area of uncertainty is the mode of action and timing of antiretroviral therapy in reducing mother-tochild transmission. In the model it was assumed that ZDV had the same proportionate effect at all stages of transmission, but there is no direct evidence to support this. An alternative possibility might be that in utero transmission occurs early, and the effect of ZDV is largely at the intrapartum stage. More data from studies using PCR and distinguishing in utero and postpartum transmission are needed to clarify this [23] . If this is correct, ZDV could have an efficacy similar to that observed in the 076 trial, at a fraction of the cost. In view of the expansion of the number of possibilities for therapy to reduce mother-to-child transmission created by the availability of new antiretroviral drugs, it can be expected that the cost and efficacy assumptions used in this study will require reconsideration as new data on different drug combinations given at different times in pregnancy become available.
The model presented here follows the ACTG 076 trial [3] in assuming that women have not been previously treated with ZDV. Preliminary data from the French Perinatal Study have reported a transmission rate of 20% in 46 women who had already received ZDV for their own disease before taking it in pregnancy [6] . For these women, as well as those who have received ZDV in a previous pregnancy, combination antiretroviral therapy is increasingly being given in the USA and in Europe. Further studies are planned or ongoing to evaluate the efficacy of other therapies in combination with ZDV in further reducing transmission in untreated and previously ZDV-treated pregnant women. If required, this model could be extended to facilitate optimal allocation of resources within a mixed population of ZDV-naive and non-naive women.
The model described in this paper focuses on a narrow condition-specific measure of cost effectiveness, the incremental cost per transmission avoided starting with an HIV-infected woman. The analysis does not take account of costs of identifying women as infected, for example in an antenatal screening programme. Moreover, while the results may be valuable to decision makers in addressing issues of resource allocation within the HIV/AIDS disease area, it is not useful for comparing across programmes. A future development will, therefore, be to use a generic outcome measure such as life years gained or quality adjusted life years to measure effectiveness, while placing the risk reduction model into an overall economic evaluation of HIV antenatal testing policies. Two studies provide estimates of the proportion of infection that occurs in utero based on the proportion of infected children who were HIV-positive by PCR at birth [26, 27] . The estimates are 0.38 [26] and 0.27 [27] , with a weighted average of 0.338 (95% CI, 0.26-0.42).
Assuming that mothers were not treated with ZDV and that approximately 10% were delivered by elective CS, then 0.338 is an estimate of u /(0.1C + 0.9V).
(Within reasonable limits, final results are insensitive to the assumptions about the proportion delivered by elective CS.)
A meta-analysis showed a 14% (95% CI, 7%-22%) difference in transmission rates between breast-fed and bottle-fed infants [2] . The studies included were carried out in Europe, and predated the use of ZDV to prevent transmission. It is assumed that the proportion of mothers who breast-feed is 10% and that this is independent of the method of delivery; 0.14 can then be considered as an estimate of (0.1 (C + b (1 -C)) + 0.9 (V + b (1 -V ))) -(0.1C + 0.9 V ) = b (1 -0.1C -0.9V ).
Finally, the parameter z can be estimated from the results of the ACTG 076 trial, which showed that overall transmission was reduced by a factor of 3.072 (95% CI, 1.69-5.59) [3] . Assuming 10% elective CS in each treatment arm, this can be taken to be an estimate of the ratio: (0.1 C + 0.9 V ) / (0.1 C z + 0.9 V z ).
The information on transmission parameters is summarized in Table 3 . The five equations can be solved to give estimates of the five parameters v, c, u, b and z. From these, the overall transmission probabilities for the intervention combinations can be derived (Fig. 1) .
The 95% CI for transmission parameters, vertical transmission rates, and ICER were obtained using Monte Carlo methods. Briefly, random numbers were drawn from each of the distributions of the five input parameters in Table 3 . The mean and standard deviations of the distributions were calculated from the published CI (Table 3 ). For each combination of random numbers, the five simultaneous equations were solved to generate new estimates of c, v, u, b and z which were then used to estimate vertical transmission rates and ICER. In cases where simulated values of c, u or b were negative (0.3% of all simulations), these were discarded. CI were based on 9999 non-negative parameter sets, such simulations being sufficient to estimate the 95% CI with a standard error of 0.7%. The simulations were also used to explore how uncertainty in parameters affected the optimum intervention strategy. The resulting intervals express the uncertainty in all the transmission parameters. Uncertainty in cost parameters was explored using sensitivity analysis. [26, 27] and assuming 10% elective CS u / (0.1 C + 0.9 V) 0.338 0.26-0.42 Difference in transmission rates, breast-fed minus bottle-fed [2] and assuming a 10% rate of elective CS:vaginal or b (1-0.1 C -0.9 V) 0.140 0.07-0.22 emergency CS vertical transmission odds ratio [24] Overall reduction in transmission due to use of ZDV [3] assuming 10% elective CS delivery (0.1 C + 0. 
